MedTrace Logo

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-06

No results posted yet for this study

Summary

This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease

Conditions

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Surveys

Patients complete the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) survey and "Was it Worth It" questionnaire.

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Patients receive stereotactic body radiation therapy (SBRT), metastasis-directed radiation therapy .

PROCEDURE

Computed Tomography

Undergo CT, MRI and/or PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo CT, MRI and/or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo CT, MRI and/or PET/CT

Sponsors & Collaborators

Principal Investigators

  • Roman O. Kowalchuk, MD · Mayo Clinic in Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2027-05-01
Completion
2032-05-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055881 on ClinicalTrials.gov